Determination of the Quantitative Content of HBsAg in Blood Serum during Complex Monitoring for Chronic Hepatitis B in HIV-Infected Patients

L.V. Moroz, T.O. Melnyk, I.A. Matkovskyi

Abstract


The paper presents the results of quantitative content of HBsAg investigation in patients with HIV/chronic hepatitis В coinfection compared with the presence/absence of hepatitis В virus DNA and alanine aminotransferase level in the blood. It has been found that in patients with HIV/chronic hepatitis В coinfection, who receive treatment, the absence of hepatitis В virus DNA is significantly associated with a reduced HBsAg level, and especially with increasing duration of treatment. When compared with the content of alanine aminotransferase, it has been revealed that HBsAg level significantly increased only in patients who did not receive antiviral treatment and have alanine aminotransferase level above normal. Thus, quantification of serum HBsAg can be considered as reliable additional criterion for monitoring the treatment of patients with HIV/chronic hepatitis В coinfection using nucleoside reverse transcriptase inhibitors.


Keywords


HIV/chronic hepatitis В coinfection; quantitative content of HBsAg; hepatitis В virus DNA; nucleoside reverse transcriptase inhibitors

References


ВІЛ-інфекція в Україні. Інформаційний бюлетень. — 2014. — № 40. — С. 3-13.

Гепатит В и ВИЧ-инфекция: тактика ведения пациентов с коинфекцией [Электронный ресурс] / Клинический протокол для Европейского региона ВОЗ (обновленная версия) // Всемирная организация здравоохранения. — 2011. — Режим доступа к протоколу: http// www.euro.who.int/PubRequest?language=Russian.

Дудина К.Р. Динамическое определение количественного содержания HBsAg в крови в сопоставлении с уровнем вирусной нагрузки у пациентов с хронической HBV-моноинфекцией / К.Р. Дудина, О.О. Знойко, С.А. Шутько и др. // РЖГГК. — 2011. — № 4. — С. 37-42.

Наказ МОЗ України № 551 «Клінічний протокол антиретровірусної терапії ВІЛ-інфекції у дорослих та підлітків» від 12.07.2010 р. — 189 с.

Максимов С.Л. Маркеры хронического гепатита В у больных ВИЧ-инфекцией и подходы к терапии / С.Л. Максимов, С.П. Царенко, А.В. Кравченко и др. // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2010. — Т. XX, № 5. — С. 22-26.

Ahn H.A. Quantification of HBsAg: Basic virology for clinical practice / Edited by Sang Hoon Ahn // World Journal of Gastroenterology. — 2011. — Vol. 17(3). — P. 283-289.

Audsley J. Factors associated with elevated ALT in an International HIV/HBV co-infected cohort on long-term HAART / Jennifer Audsley, Eric C. Seaberg, Joe Sasadeusz et al. // PLoS one. — 2011. — Vol. 6(11). — P. 1-7.

Brook G. British HIV Association guidelines for the management of co-infection with HIV-1 and hepatitis B or C virus / G. Brook, J. Main, M. Nelson et al. // HIV Medicine. — 2010. — Vol. 11. — P. 1-30.

Brunetto M.R. A new role for an old marker, HBsAg / Maurizia Rossana Brunetto // Journal of Hepatology. — 2010. — Vol. 52. — P. 475-477.

Buti M. Quantification of hepatitis B virus HBsAg: clinical implications / Buti M., Rodríguez Frías F., Esteban R. // Medicina Clinica. — 2012. — Vol. 138(11). — P. 483-488.

Emiroglu N. Viral hepatitis burden and policy directions in the European region of WHO / Nedret Emiroglu // Summit Conference on Hepatitis B and C. — 14–15 October 2010. — Brussels. — 20 p.

Kosi L. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients / Kosi L., Reiberger T., Payer B.A. et al. // Journal of Viral Hepatitis. — 2012. — Vol. 19(11). —

P. 801-810.

Miailhes P. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion / Miailhes P., Trabaud M.A., Pradat P. et al. // Clinical Infectious Diseases. — 2007. — Vol. 45(5). — P. 624-632.

Mallet V. The impact of human immunodeficiency virus on viral hepatitis / Vincent Mallet, Anaıs Vallet-Pichard, Stanislas Pol et al. // Liver International. — 2011. — Vol. 1. — P. 135-139.

Marcellin P., Buti M., Gane E.J., Krastev Z., Flisiak R., Germanidis G. et al. Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis // Hepatology. — 2011. — 54. —

A.

Martinot-Peignoux M. The role of HBsAg quantification for monitoring natural history and treatment outcome / Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah et al. // Liver International. — 2013. — Vol. 1. — P. 125-132.

Papatheodoridis G. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection / G. Papa-theodoridis, M. Buti, M. Cornberg et al. // Journal of Hepatology. — 2012. — Vol. 57. — Р. 16-185.

Pol S. Management of HBV in immunocompromised patients / Stanislas Pol // Liver International. — 2013. — Vol. 1. — P. 182-187.




DOI: https://doi.org/10.22141/2312-413x.3.04.2014.82430

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru